Directed new share issue in BerGenBio´s ASA (NO) — NOK 220 million

Carnegie acted as joint bookrunner in the directed new share issue of 12,215,318 shares at a subscription price of NOK 18.0 per share. BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. January 2020.